<DOC>
	<DOC>NCT01477931</DOC>
	<brief_summary>The aims of this study are 1) to examine the clinical utility of bupropion hydrochloride extended release (Wellbutrin XL速) in patients with Major Depressive Disorder (MDD) with atypical features; 2) to evaluate the tolerability of bupropion hydrochloride extended release (Wellbutrin XL速) in patients with MDD with atypical features.</brief_summary>
	<brief_title>Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features</brief_title>
	<detailed_description>Whether bupropion hydrochloride extended release (Wellbutrin XL速) improved atypical depressive symptoms has not been investigated. The investigators assumed that bupropion hydrochloride extended release (Wellbutrin XL速) will be effective and tolerable in the treatment of atypical depression in MDD patients.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Age over 20 years DSMIV episode of MDD nonpsychotic with atypical features characterized by mood reactivity and 2 or more symptoms of vegetative reversal (including overeating, oversleeping, severe fatigue or leaden paralysis, and a history of rejection sensitivity) More than 19 score on the 29item HAMD Ability to give informed consent Bipolar depression Any Axis I psychotic disorder A history of suicide attempt, selfinjurious action (excluding action with no intention of suicide) or overdosage (excluding apparently accidental overdosage) Patients with more than 3point score of suicide (HAMD29 Item 18) or patients whose CSSRS assessment suggests that they are or have been at significant risk for harming themselves or have actually harmed themselves, or who, in the opinion of the investigator (subinvestigator), are at significant risk for harming self or others A history of substance abuse in the previous 12 months A history of hypersensitivity to bupropion or any other components of the preparations used in the study (Wellbutrin SR 150mg and Wellbutrin XL 300 mg tablets) Serious or unstable medical disorders Starting or terminating psychotherapy during the previous 12 weeks, ECT treatment in the previous 3 months Subject has a life time diagnosis of anorexia nervosa or bulimia within the past 12 month Subject has a current or history of seizure disorder or brain injury (traumatic or diseaserelated) or any condition which predisposes to seizure subject treated with other medications or treatment regimens that lower seizure threshold subject undergoing abrupt discontinuation of alcohol or sedatives Subjects that previously failed adequate courses of pharmacotherapy from two different classes of antidepressants or previous adequate course(s) of bupropion Pregnancy or planning pregnancy when a patient is in active reproductive age, he or she has to agree to use relevant contraception during the study Patients on monoamine oxidase inhibitors (MAOIs) Patients being treated with any other preparations containing bupropion as the incidence of seizures is dose dependent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Bupropion hydrochloride extended release</keyword>
	<keyword>Wellbutrin XL</keyword>
	<keyword>Major Depressive Disorder with Atypical Features</keyword>
</DOC>